Trained as an immunologist at the Pasteur Institute (Paris, France), Prof. Steve Pascolo used mouse models to test and develop mRNA-based vaccines (direct injection of mRNA) during his post-doc in Tuebingen, Germany from 1998 till 2000. In 2000, he co-founded CureVac with Dr. Hoerr and Dr. von der Mulbe. Dr. Pascolo was Chief Scientific Officer (CSO) of the company from 2000 till 2006, developing the technology, implementing the worldwide first GMP production of mRNA and in 2003 performing the worldwide first mRNA vaccine clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he joined the oncology department of the University Hospital of Zurich, Switzerland and continued the development of immunotherapies based on RNA.
In 2008, he founded Miescher Pharma to support this work. In 2017, Dr. Pascolo implemented in Zurich an academic mRNA platform https://www.cancer.uzh.ch/en/Research/mRNA-Platform.html. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.
